20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
16
10
2018
medline:
29
5
2021
entrez:
16
10
2018
Statut:
ppublish
Résumé
The aim of this study was to evaluate metastatic latency and survival after the occurrence of metastases in patients with choroidal/ciliary body melanoma treated with proton therapy. This was a retrospective cohort study. All consecutive patients with choroidal/ciliary body melanoma treated with proton therapy between 1991 and 2010 were included. Overall survival, specific survival (SS), local recurrence-free interval, and metastasis-free interval (MFI) were calculated. There were 508 patients. The mean follow-up was 239.4 months. Overall survival and SS rates were 57.2 and 67.6% at 10 years. Pre-equatorial tumor location, advanced tumor stage, and initial exudative retinal detachment were associated independently with SS. Thirty-three percent of the patients (n = 169) had metastases. Local recurrence-free interval and MFI were 91.3 and 65.7% at 10 years, respectively. MFI was shorter in pre-equatorial, large tumors, and/or tumors with exudative retinal detachment. After the occurrence of metastases, the median survival time was 1.25 years and survival probabilities were 62.1% at 1 year, 26.0% at 2 years, and 6.0% at 5 years. Except for age, none of the baseline clinical factors was associated with survival after metastasis occurrence. SS after metastasis occurrence was longer for metastasis occurring more than 10 years after tumor diagnosis (P =0.010). Death after metastasis is independent of initial tumor characteristics. Small tumors still have a risk for metastases after 10 years. Thus, lifelong follow-up is necessary for uveal melanoma patients. Larger series of metastatic patients are needed to evaluate aggressive multimodal treatments of metastases. Death after metastasis is independent of the initial tumor characteristics. Small tumors contraintuitively have a long-life risk of metastases. MFI is associated independently with pre-equatorial location, tumor stage, and retinal detachment.
Identifiants
pubmed: 30320630
doi: 10.1097/CMR.0000000000000519
pii: 00008390-202006000-00007
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
272-278Références
Vidal JL, Bacin F, Albuisson E, Rozan R, Desjardins L, D’Hermies F, et al. ‘Melanoma 92’. epidemiological study of uveal melanoma in France. J Fr Ophtalmol. 1995; 18:520–528
Swerdlow AJ. Epidemiology of eye cancer in adults in England and Wales, 1962–1977. Am J Epidemiol. 1983; 118:294–300
Paul EV, Parnell BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin. 1962387–402
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118:1881–1885
Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943–1982. Int J Cancer. 1987; 40:161–164
Collaborative Ocular Melanoma Study Group (1998). Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998; 125:745–766
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 20097th edition, New York, NY: Springer Science and Business Media LC
Hosten N, Bornfeld N, Wassmuth R, Lemke AJ, Sander B, Bechrakis NE, et al. Uveal melanoma: detection of extraocular growth with MR imaging and US. Radiology. 1997; 202:61–67
Gass JD. Observation of suspected choroidal and ciliary body melanomas for evidence of growth prior to enucleation. Retina. 1980; 23:523–528
Rouberol F, Roy P, Kodjikian L, Gérard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol. 2004; 137:893–900
Gambrelle J, Kodjikian L, Grange JD. Survival after primary enucleation of largest uveal melanomas. Acta Ophthalmol Scand. 2005; 83:398–399
Kodjikian L, Roy P, Rouberol F, Garweg JG, Chauvel P, Manon L, et al. Survival after proton-beam irradiation of uveal melanomas. Am J Ophthalmol. 2004; 137:1002–1010
Krengli M, Munzenrider J, Suit H. Amaldi U, Larsson B, Lemoigne Y. Clinical experience with proton beam therapy at MGH, MEEI, and HCL: skull base sarcoma and uveal melanoma. Advances in hadrontherapy. 1997, Amsterdam: Elsevier95–102
Egger E, Zografos L. Amaldi U, Larsson B. Proton beam irradiation of uveal melanoma at PSI: latest results. Hadrontherapy in oncology. 1994, Amsterdam: Elsevier145–149
Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys. 2001; 49:1053–1059
Grange JD, Joschi G, Gerard J, Jean-Louis B, Sentenac I, Ayzac L, et al. Results of 10 years’ experience with contact beta-therapy with Ruthenium 106 applicators for uveal melanoma. Review of 207 cases and tribute to PK Lommatzsch [translation]. Ophtalmologie. 1995; 9:317–323
Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992; 110:245–250
Gragoudas ES, Seddon JM, Egan KM, Polivogianis L, Hsieh CC, Goitein M, et al. Prognostic factors for metastasis following proton beam irradiation of uveal melanomas. Ophthalmology. 1986; 93:675–680
Vrabec TR, Augsburger JJ, Gamel JW, Brady LW, Hernandez C, Woodleigh R. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology. 1991; 98:984–988
Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983; 101:1894–1899
Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996; 347:1222–1225
Diener West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992; 110:245–250
Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006; 65:780–787
Gragoudas ES, Egan KM, Seddon JM, Walsh SM, Munzenrider JE. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology. 1992; 99:760–766
Bacin F, Kwiatkowski F, Dalens H, Rozan R, Gagyi S, Donnarieix D, et al. Long-term results of cobalt 60 curietherapy for uveal melanoma. J Fr Ophtalmol. 1998; 21:333–344
Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology. 1999; 106:1579–1587
Buzzacco DM, Abdel-Rahman MH, Park S, Davidorf F, Olencki T, Cebulla CM. Long-term survivors with metastatic uveal melanoma. Open Ophthalmol J. 2012; 6:49–53
Macdonald EC, Cauchi P, Kemp EG. Proton beam therapy for the treatment of uveal melanoma in Scotland. Br J Ophthalmol. 2011; 95:1691–1695
Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol. 2009; 127:423–429
Singh AD, Wang MX, Donoso LA, Shields CL, De Potter P, Shields JA. Genetic aspects of uveal melanoma: a brief review. Semin Oncol. 1996; 23:768–772